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Abstract: Alström syndrome is a rare autosomal recessive genetic disorder characterized by cone-rod dystrophy, hearing 
loss, childhood truncal obesity, insulin resistance and hyperinsulinemia, type 2 diabetes, hypertriglyceridemia, short 
stature in adulthood, cardiomyopathy, and progressive pulmonary, hepatic, and renal dysfunction. Symptoms first appear 
in infancy and progressive development of multi-organ pathology leads to a reduced life expectancy. Variability in age of 
onset and severity of clinical symptoms, even within families, is likely due to genetic background.  
Alström syndrome is caused by mutations in ALMS1, a large gene comprised of 23 exons and coding for a protein of 
4,169 amino acids. In general, ALMS1 gene defects include insertions, deletions, and nonsense mutations leading to 
protein truncations and found primarily in exons 8, 10 and 16. Multiple alternate splice forms exist. ALMS1 protein is 
found in centrosomes, basal bodies, and cytosol of all tissues affected by the disease. The identification of ALMS1 as a 
ciliary protein explains the range of observed phenotypes and their similarity to those of other ciliopathies such as Bardet-
Biedl syndrome. 
Studies involving murine and cellular models of Alström syndrome have provided insight into the pathogenic mechanisms 
underlying obesity and type 2 diabetes, and other clinical problems. Ultimately, research into the pathogenesis of Alström 
syndrome should lead to better management and treatments for individuals, and have potentially important ramifications 
for other rare ciliopathies, as well as more common causes of obesity and diabetes, and other conditions common in the 
general population. 
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INTRODUCTION  
  Alström syndrome (OMIM 203800) is a rare autosomal 
recessive genetic disorder, thought to have a prevalence of 
less than one per million in the general population. It is 
characterized by the progressive development of multi-organ 
pathology [1-3]. Symptoms first appear in infancy with great 
variability in age of onset and severity of clinical symptoms, 
even within families bearing identical mutations [4]. The 
severity of the disease, often leading to organ failure,   
results in a reduced life expectancy, rarely exceeding 50 
years.  
  Alström syndrome encompasses cone-rod dystrophy in 
infancy, hearing loss, childhood truncal obesity, 
hyperinsulinemia and insulin resistance, type 2 diabetes 
mellitus (T2DM), hypertriglyceridemia, short stature in 
adulthood, dilated cardiomyopathy (DCM), and progressive 
pulmonary, hepatic, and renal dysfunction. Fibrosis of 
unknown etiology develops in multiple organs [4]. The 
clinical care of individuals is complex due to the 
combination of multiple endocrine disorders, sensorineural 
deficits, cardiac, renal, and hepatic abnormalities. There is 
no specific therapy and individuals are treated and monitored 
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on the basis of individual symptoms. A diagnosis is usually 
established on the basis of clinical features observed but may 
be delayed as a result of gradual evolvement and variable 
expression [2,3].  
  Since Alström syndrome is caused by mutations in the 
ALMS1 gene, molecular genetic analysis can be used to 
confirm the clinical diagnosis [5-7]. The identification of 
two mutated alleles or a single mutated ALMS1 allele in the 
presence of four age-dependent primary features or three 
primary features plus two age-dependent secondary features 
are criteria for diagnosis [3]. Heterozygous carriers are 
asymptomatic, and testing for at-risk relatives, prenatal 
diagnosis, and preimplantation genetics usually requires 
prior identification of disease-causing mutations in the 
family. A screening strategy that first targets the regions of 
the gene where most of the mutations occur (exons 16, 10, 8) 
has been successfully used [8-10]. Additionally, the recent 
development of arrayed primer extension (APEX) 
technology can be used as an efficient and cost-effective first 
pass screening tool for known single base substitutions, 
deletions and insertions in ALMS1 and for 10 known genes 
causing a similarly related disorder, Bardet-Biedl syndrome 
(BBS) (Asper Biotech (www.asperbio.com)) [11]. Next 
generation sequencing technology and target capture offers 
new efficient and cost effective means for identifying 
ALMS1 mutations and will be useful for carrier testing [12]. 226    Current Genomics, 2011, Vol. 12, No. 3  Marshall et al. 
  The primary ocular differential diagnoses, due to the 
severe retinal dystrophy and visual impairment during the 
first months of life, include cone dystrophies such as Leber’s 
congenital amaurosis (LCA), and achromatopsia. Often an 
initial diagnosis of LCA is revised as further characteristic 
metabolic phenotypes emerge. In addition, infants with 
DCM and congestive heart failure (CHF) commonly receive 
a diagnosis of idiopathic infantile DCM, infectious 
myocarditis, immune abnormalities, or mitochondrial 
dysfunction. The phenotypic characteristics of Alström 
syndrome also resemble Bardet-Biedl syndrome (BBS), a 
multi-system disease that has the closest clinical similarity to 
Alström syndrome. Other differential diagnoses include 
Wolfram, Cohen, Biemond II and Usher syndromes.  
  Despite its rarity, there is considerable interest in 
understanding the molecular basis and biochemical pathways 
of Alström syndrome as a monogenic model for metabolic 
syndrome with obesity, insulin resistance, diabetes mellitus, 
hypertriglyceridemia and hypertension as common features. 
Additionally, other clinical features, such as retinal 
degeneration, sensorineural hearing loss, cardiomyopathy, 
and hepatic and renal failure, are common in the general 
population.  
  The normal function of the ALMS protein and the 
reasons that its disruption leads to the diverse phenotypes 
remain unclear, although roles in ciliary function, 
intracellular trafficking and, most recently, adipocyte 
differentiation have been reported [13-17]. Identification of 
monogenic forms of obesity, such as Alström syndrome, and 
continued research into rare obesity-related disorders can 
expand our understanding of the mechanisms of energy 
homeostasis, body weight regulation, and endocrine 
function. 
ALSTRÖM SYNDROME CLINICAL OVERVIEW 
Neurosensory Deficits 
  Nystagmus and extreme photophobia or light sensitivity 
characterizes the ocular presentation of infants and very 
young children with Alström syndrome. Visual dysfunction 
is usually demonstrated within a few weeks after birth, with 
only weak activity in cone electroretinography (ERGs) at 6 
months of age or less. By 2.5 years, full-field ERG findings 
often include severely reduced or extinguished responses 
with a typical pattern of cone dystrophy and subnormal rod 
activity. Visual evoked potential (VEP) amplitudes are 
severely reduced. Rods are preserved initially, but by 5 
years, rods are beginning to be destroyed and responses can 
become unrecordable. Complete blindness usually occurs in 
the second decade [18]. However, phenotypic variation in 
age of onset and rate of progression is observed [8]. Bilateral 
subcapsular cataracts are common, and their removal can 
temporarily improve light perception. Retinal pathological 
changes developing in childhood also include attenuation of 
retinal vessels, optic disc pallor, and increasingly significant 
retinal pigmentary epithelial (RPE) atrophy. Histological 
studies demonstrate asteroid hyalosis, optic disc drusen, and 
bone spicules [8,18-20]. Optical coherence tomography 
(OCT) imaging in a 5 year old child showed thinning of the 
macula and an early arrest of macular development with 
immature retinal structural organization [9]. No therapy 
exists for the progressive vision loss, but early intervention 
with low vision aids and magnifiers, mobility training, and 
Braille should be undertaken in children in expectation of 
future blindness.  
  Eighty-nine percent of individuals develop slowly 
progressive bilateral sensorineural hearing loss in the first 
decade that usually progresses to the moderate –to- severe 
range. However, age of onset and severity is variable and can 
develop anytime from onset in infancy to adulthood [21,22]. 
Further, chronic and acute otitis media in childhood often 
exacerbates the sensorineural deficits with a component of 
conductive hearing loss [4]. Myringotomy can be of benefit 
in some individuals with chronic otitis media. Cochlear 
implantation also has been successful, but surgery 
complications are known to occur in this rare syndrome [23]. 
Obesity 
  Obesity is an early and consistent feature observed in 
most children with Alström syndrome [3, 4]. However, birth 
weight and body mass index (BMI kg/m
2) are in the normal 
range during the first few months of life. Significant and 
rapid weight gain begins within the first or second year and 
remains a medically significant problem, particularly in 
childhood (Fig. 1). The distribution of adipose tissue is 
widespread but predominantly distributed subcutaneously 
and viscerally. Dual energy x-ray absorptiometry (DEXA) 
scans have estimated total body fat in the top 25th centile 
[24,25]. BMI for males and females range between 21 and 
53 [4]. BMI tends to normalize in older individuals, whereas 
insulin resistance continues to increase [24, 26]. The 
moderation of BMI with age does not correlate with the 
onset of renal or heart failure and T2DM [24]. 
  Decreased levels of physical activity, often exacerbated 
by dual neurosensory losses, have been observed in Alström 
syndrome, but no formal metabolic studies have been 
undertaken. Although childhood hyperphagia has been 
proposed as a possible issue contributing to obesity, the 
evidence remains anecdotal [4, 27, 28]. A combination of 
disordered appetite regulation and decreased physical 
activity could, therefore, contribute to the development of 
obesity in this disorder.  
  Leptin levels are elevated in Alström syndrome and 
correlate with body weight [29]. However, mild elevations in 
leptin levels normalized to BMI, suggest leptin resistance 
[30]. No formal trials to manage obesity with appetite 
suppressors or lipase inhibitor therapies have been reported.  
Type 2 Diabetes Mellitus  
  Severe insulin resistance, hyperinsulinemia, and impaired 
glucose tolerance often present in very early childhood and 
are frequently accompanied by acanthosis nigricans. Even 
when matched for pubertal stage and body composition, 
individuals with Alström syndrome are much more severely 
insulin resistant than controls [24]. T2DM develops in 
childhood, adolescence, or adulthood, with a mean age of 
onset at 16 years [4].  
  Reduced carbohydrate intake may prove more effective 
than fat restriction for control of hyperglycemia and 
hyperinsulinemia in a subset of individuals with Alström Alstrom Syndrome  Current Genomics, 2011, Vol. 12, No. 3    227 
syndrome [31]. Lee and colleagues [28] described 
moderation of hyperinsulinemia with strict caloric restriction 
in a young child with Alström syndrome [32]. Metformin 
and dipeptidyl peptidase 4 (DPP4) inhibitors have been 
effective in some individuals [26,31]; however, the 
hyperglycemia can be intractable thus requiring insulin to 
achieve glycemic control [33]. Unlike in the general 
population, the onset of T2DM appears unrelated to the 
degree of obesity, and protection from clinical peripheral 
sensory neuropathy has been suggested [34].  
Dyslipidemia 
  Children with Alström syndrome often have high lipid 
levels at an early age. Hypertriglyceridemia is variable and 
not always accompanied by hypercholesterolemia. There is 
no apparent correlation between high triglycerides and 
insulin resistance, hyperinsulinemia, or obesity [35]. The 
hypertriglyceridemia can be sufficiently severe to cause 
pancreatitis [36, 37]. An increased risk for cardiovascular 
disease has been suggested due to the complications of 
obesity, severe insulin resistance, T2DM, and renal 
impairment from an early age [38]. However, MRI imaging 
studies have shown that cardiac and renal failures found in 
Alström syndrome are not associated with vascular disease 
in the coronary artery [39]. 
Cardiomyopathy  
  DCM and CHF manifest in approximately two-thirds of 
individuals with Alström syndrome at some stage during 
their lives and are major causes of morbidity and mortality. 
Individuals are at risk of sudden abrupt onset of CHF at any 
age, but often during infancy with onset in the first weeks of 
life prior to the appearance of other clinical features of 
Alström syndrome [3, 40, 41]. Many of these infants survive 
with apparent recovery of cardiac function following 
treatment. However, after a variable interval of normal to 
low-normal cardiac function, CHF can suddenly recur in 
adolescence or adulthood with involvement of both 
ventricles, rapid progression, and a poor clinical prognosis. 
Another subset of individuals develop adult or adolescent 
onset CHF, which appears to be a fibrotic process causing 
myocardial hypertrophy and dilation with restrictive 
impairment of both ventricles [39, 42]. Significantly decre-
ased systolic wall motion velocities and amplified aortic 
systolic pressure are indicative of central arterial stiffening 
that may contribute to the development of cardiomyopathy 
[43, 44]. Heart transplantation is problematic, with a poor 
success rate because multiple organs are compromised in this 
syndrome. However, successful cardiac transplantation has 
been reported [45].  
Hepatic Pathology 
  There is extensive phenotypic variation in the slowly 
progressive hepatic dysfunction in Alström syndrome, which 
begins with clinically silent elevation of transaminases, and 
steatosis [46-48]. The initial presentation is usually steatosis 
and hepatosplenomegaly followed by fibrotic and 
inflammatory processes with lymphocytic infiltration in the 
portal and parenchymal areas. Hepatocellular adenoma with 
pericellular fibrosis has been described [49]. In the final 
course of hepatic disease, there is significant fibrosis, 
cirrhosis, portal hypertension, esophageal varicies, 
encephalopathy, with upper GI hemorrhage leading to death. 
Inflammatory changes resulting in fibrosis do not appear to 
be autoimmune related because antinuclear antibodies and 
other typical markers of autoimmune hepatitis are negative. 
End stage liver disease is the cause of death in about 10% of 
individuals [4].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). A, B. Clinical pictures of a male with Alström syndrome at 
the age of 6 years, 8 months presenting characteristic truncal 
obesity. C. Note characteristic face and prominent ears. 228    Current Genomics, 2011, Vol. 12, No. 3  Marshall et al. 
Renal Disease 
  Manifestations of progressive renal impairment include 
varying degrees of glomerular disease with reduced 
glomerular filtration rate and albuminuria. Decreased urine-
concentrating capacity, hypertension, renal tubular acidosis, 
polyuria and polydipsia develop over time. Nephrocalcinosis 
has been described [50] along with histopathologic focal 
glomerulosclerosis and interstitial renal fibrosis [4,51].  
  Lower urinary tract dysfunction, recurrent infections, 
vesicoureteral reflux, urethral stenosis, and detrusor 
instability have been reported [4, 35]. Urologic dysfunction 
may require indwelling catheterization. End-stage renal 
disease (ESRD) can occur as early as the late teens and is a 
major cause of morbidity. Renal and renal-pancreas 
transplantation in affected individuals has been successful, 
although obesity and other compromised organs can render 
the individual unsuitable for the procedure [52]. 
Hypogonadism 
  Hyper- or hypogonadotropic hypogonadism is seen in 
both males and females but is more frequent in males. Low-
normal levels of testosterone and elevated gonadotropins are 
suggestive of a primary gonadal failure [53,54]. Males have 
small external genitalia and testicular atrophy with 
obliterating fibrosis of seminiferous tubules [4]; however, 
sporadic spermatozoa can be found in the seminal fluid. 
Secondary sex characteristics are normal. 
  Hypogonadism may not be apparent in females until 
puberty when delay in onset of secondary sex characteristics 
and menarche become evident. Affected females may have 
hyperandrogenism, hirsutism, and alopecia, which are 
probably related to insulin resistance [10]. Pathological 
examination reveals cystic ovaries with dense fibrotic 
changes, minimal or absent primary or secondary follicles 
and no corpora lutea [4]. Abnormal breast development, 
precocious puberty, endometriosis, irregular menses or 
amenorrhea has been reported. As children approach 
puberty, gonadotropin and sex hormone levels should be 
monitored to determine if hormone replacement therapy is 
indicated. Metformin, progesterones, or estrogen-
progesterone medications have ameliorated cycle regulation 
in females. No individuals with Alström syndrome are 
known to have reproduced.  
Endocrine Disturbances 
  Prior to puberty, children typically have a height above 
the 50th percentile, with rapid growth and a bone age 
advanced by 1-3 years [4]. However, the early growth 
velocity declines as the child matures, and most adolescents 
and adults have a final short stature. Abnormalities of the 
insulin-like growth factors (IGFs) system and growth 
hormone deficiency have been reported [29,55-58]. 
Although pituitary dysfunction might explain, at least in part, 
short stature in Alström syndrome, very few studies have 
specifically addressed this and speculation about the possible 
effects of growth hormone replacement therapy remains 
controversial [56-59]. Secondary and sub-clinical 
hypothyroidism have been reported in a subset of 
individuals, suggestive of a hypothalamic defect [4,27,35]. 
No alterations of prolactin or pituitary-adrenal axes have 
been reported to date. 
Respiratory Illness 
  Chronic respiratory tract infections beginning in early 
childhood, leading to chronic bronchitis, asthma, and chronic 
rhinosinusitis is common, particularly in children. 
Pulmonary problems range in severity from frequent 
bronchial infections to chronic obstructive pulmonary 
disease (COPD) and acute respiratory distress syndrome 
(ARDS).  Pulmonary hypertension is common and 
histopathological studies have shown early morphological 
changes indicating an inflammatory process in the small 
airways. Severe interstitial, obliterating fibrosis has been 
reported, [4] with some individuals not able to maintain 
adequate oxygen saturation and requiring  continuous 
positive air pressure (CPAP). Blood oxygen saturation can 
plummet rapidly, particularly during or following surgical 
procedures [23,60]. 
Neurologic and Developmental Abnormalities 
  Most individuals with Alström syndrome demonstrate 
normal intelligence, although mild to moderate delay in 
reaching major developmental milestones including gross 
motor and fine motor skills and intellectual development 
have been reported [40,61]. The delays in early milestones 
could be due to sensory deficits although autistic spectrum 
behaviors and seizure activity have been reported [4]. 
Balance disturbances have been observed [62,63] but 
without ataxia or impaired coordination. Some individuals 
lack facial movement sometimes associated with speech 
difficulty [62]. Cerebellar anomalies have been noted [64]. 
Although there are some individuals with Alström syndrome 
that seem to be totally free of psychological issues, major 
depression, obsessive-compulsive behavior, and psychotic 
behavior have been noted, particularly in adults and there are 
a range of classic medications that have been administered.  
It remains to be investigated whether psychological 
problems are primary or secondary to vision and hearing 
impairment and general ill health. 
Other Abnormalities 
  Distinctive facial characteristics are reported in Alström 
syndrome such as deep-set eyes with a rounded face, 
hyperostosis frontalis interna, thick ears, premature frontal 
balding, and thin hair (Fig. 1). Most children have 
characteristic wide, thick and flat feet, and short stubby 
fingers and toes with brachydactyly, but with no polydactyly 
or syndactyly [4] (Fig. 2). Scoliosis and kyphosis are 
frequent and variable in severity and compound cardiac 
problems by restricting lung function. Individuals may 
present with chronic abdominal pain, abdominal distension 
or constipation which  may resolve spontaneously. Cecal 
volvulus has been reported [60]. 
  Dental anomalies such as absent, mislocated or extra 
teeth are reported and can include gingivitis and light 
yellow-brown discolored enamel bands on the anterior teeth. 
Histological examination of the gingiva has revealed 
irregular thickness of the basal lamina and delamination of 
the myelin sheath [65].  Alstrom Syndrome  Current Genomics, 2011, Vol. 12, No. 3    229 
GENETICS 
  Alström syndrome is caused by mutations in the ALMS1 
gene, located on chromosome 2p13, and is inherited as an 
autosomal recessive disorder. Heterozygous carriers are 
asymptomatic [27]. In contrast to BBS, cases of tri-allelic 
inheritance have not been reported.  
ALMS1 Gene Structure and Expression 
  Originally described by Collin et al. [5] and Hearn et al. 
[6],  ALMS1 is composed of 23 exons. There is strong 
evidence for several alternatively spliced transcripts. 
However, the exonic structure of the individual cDNAs has 
not yet been conclusively identified [5]. Purvis et al. [66] 
characterized the transcription start site (TSS) of the ALMS1 
gene and examined several tissues which showed multiple, 
tissue-specific TSSs spanning a 70bp region. In silico 
analysis revealed putative transcription factor binding sites 
including X-box and three GC-box like elements. Deletion 
constructs lacking these binding sites have resulted in 
reduced promoter activity. Since X-box and GC boxes are 
target sites for RFX and Sp/KLF transcription factors, 
respectively, targeted mutations were used to show that they 
disrupted the binding of RFX members and Sp1. Reporter 
assays showed that Sp1 and RFX proteins can affect the 
transcription of ALMS1. ChIP analysis confirmed the binding 
of RFX1 and 2 to ALMS1 in vivo. RNAi experiments 
validated the involvement of RFX factors in the upregulation 
of  ALMS1 specifically following serum starvation [66]. 
Interestingly, RFX transcription factors regulate genes 
involved in ciliary assembly supporting a role for ALMS1 in 
the function/maintenance of cilia. 
 ALMS1 is expressed in most tissues affected in Alström 
syndrome, including the organ of Corti, retinal 
photoreceptors, renal tubules, liver, and pancreatic islets 
[5,14,67]. In the brain, ALMS1 is found widely expressed in 
most regions including the hypothalamus (http://www.brain-
map.org). Several splice variants of ALMS1 have been 
described encoding isoforms of the protein [5,13,14]. Some 
protein isoforms show distinct intracellular localization since 
antibodies directed against the N-terminal part of the protein 
label the centrosomes in cells, antibodies against the C-
terminus stain the cleavage furrow of dividing cells. 
Different ALMS1 isoforms may perform different functions 
in the cell. 
 The  longest  ALMS1 transcript potentially encodes a 461 
kDa protein of 4169 amino acids. Exon 1 contains a tract of 
glutamic acid residues (aa 13–29) consisting of a 
(GAG)NGAA(GAG)3 repeat, followed by a stretch of seven 
alanine residues (aa 3036) [5, 6]. Exon 8, a large 6-kb exon, 
contains a large tandem repeat domain encoding 34 
imperfect repeats of 45–50 amino acids. This domain 
constitutes 40% of the protein [6]. Potential nuclear 
localization signals (aa 3805-3830; aa 3937-3954) are found 
near the carboxy terminus. The carboxy end of the protein 
represents an evolutionarily conserved motif, termed the 
ALMS motif, which shares sequence similarity with two 
other centrosomal proteins, C10orf90 and KIAA1731 [6,68]. 
Although deletion constructs containing the ALMS motif 
localized to the centrosome, Knorz et al. [68] found that this 
motif was not critical for centrosome targeting. 
  At least one isoform of ALMS1 prominently localizes to 
the centrosomes and basal bodies of ciliated cells. 
Centrosomes are the microtubule organizing centers of the 
cell that orchestrate essential aspects of cell division and 
signaling pathways such as Sonic Hedgehog and WNT, 
through the primary cilium, respectively [69,70]. Knorz et al. 
[68] showed that ALMS1 interacts with and perhaps anchors 
the centrosome cohesion protein, CNAP1, to the distal 
region of basal bodies. Interestingly, CNAP1 has been 
shown to be important for the linkage between the two basal 
bodies formed by rootletin fibers [71].  
Genetic Variation 
  To date, 109 different mutations in ALMS1 have been 
identified in individuals with Alström syndrome and the 
majority are nonsense and frameshift (insertions or 
deletions) that result in premature termination codons [5-
8,10,11,72-73]. A preponderance of disease causing 
mutations described thus far are located in the coding 
regions of exons 8, 10 and 16 (Fig. 3) with mutations in exon 
16, accounting  for 36% of the total mutational load in 
Alström syndrome [11,24,73]. Common mutations identified 
include c.11449C>T; p.Q3817X and c.11313_11316del 
TAGA; p.D3771fs, and c.10483C>T; p.Q3495X, each 
identified in 10 unrelated families. Founder effects have 
been observed in certain ethnic backgrounds: a 19 basepair 
insertion, c.10539_10557ins(n)19; p.H3512fs, has been 
observed in families of Acadian origin, a 10775delC 
insertion in UK families, and an IVS8 + 895del1444 deletion 
in Pakistani families [5,7,41]. The lack of disease causing 
mutations in the 5’ half of the coding region of ALMS1 
(exons 1 through 7) prompts the speculation that mutations 
in this region are embryonic lethal. This is supported by the 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2).  A. Close-up of broad hands with stubby fingers and 
brachydactyly from a 3 year, 3 month old child with Alström 
syndrome. B. Pes planus typically seen in Alström syndrome. 230    Current Genomics, 2011, Vol. 12, No. 3  Marshall et al. 
finding in cell culture that knockdown with siRNA targeted 
to the 5’-end prevents formation of primary cilia [16]. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Summary of known mutations in ALMS1  gene. This 
includes 94 published alterations [5-11,24,51,72,73] and 15 
additional unpublished mutations.  
  A total of 222 unique SNPs in the human ALMS1 gene 
are listed in the public SNP database which is available at 
http://uswest.ensembl.org/Homo_sapiens/Gene/Variation_G
ene/Table?db=core;g=ENSG00000116127;r=2:73612886-
73837920;t=ENST00000264448, March, 2011. SNPs 
located within the coding region of ALMS1 show a 
somewhat similar distribution as that observed with disease 
causing mutations with a trend for higher SNP density 
towards the 3’ half of the coding region. Among these, 111 
SNPs currently listed in the ENSEMBL database 
[ENSEMBL, http://www.ensembl.org] lead to non-
synonymous coding changes (ascertained in several 
population surveys). Among these variations is a stop codon 
in exon 8 (7126G>T, rs34997036) with an allele frequency 
of 0.014. Since known ALMS1 mutations have been 
identified close by, such a change can be expected to cause 
the disease in either a homozygous state or as a compound 
heterozygote together with another ALMS1 mutation. In 
addition, in the general population there are two insertions 
causing a frameshift and predicted premature termination 
(2048insC, rs344442050; 11983insT, rs34465329), which 
might be expected to be disease alleles. Assuming the high 
allele frequencies are not artifacts of the yet low coverage of 
the general population (~100 individuals), one might expect 
the disease to be more prevalent. This is not entirely 
implausible considering the high variability in phenotype 
and the results from murine studies indicating that most 
Alström syndrome phenotypes are strongly modified by the 
genetic background which may result in a less obvious 
clinical phenotype. 
 The  ALMS1 gene shows an unusual population structure 
and evolutionary history. It is one of several genes that 
shows strong positive recent selection, on par with lactase 
persistence and resistance to malaria, and among the 
strongest selection estimated for humans [74]. The 
prevalence of specific haplogroups in African, European and 
Asian populations was best explained by selection of 
preexisting variation in Eurasian populations about 15,000 
years ago. It is currently unclear what the selective pressure 
acting on ALMS1 might be, although Scheinfeld et al. [74] 
point out that several other regions of selection in the human 
genome have been associated with carbohydrate metabolism. 
Interestingly, SNP rs7598660 was found to be weakly 
associated with several insulin and glucose related traits, 
such as 2 hour insulin levels, with the ancestral allele linked 
to higher insulin levels or greater insulin resistance. 
Although it is unlikely that this association is causally 
related to the selective sweep in Eurasians, it is possible that 
a variation in ALMS1 contributing to insulin resistance was 
carried on the selected haplotype, and may today contribute 
to the higher incidence of insulin resistance in Americans of 
African ancestry compared to those with European ancestry 
[74].  
Association Studies 
  Correlation studies have examined whether some of the 
phenotypic variation in Alström syndrome individuals could 
be attributed to allele specificity. In small-scale studies (12 
Alström syndrome  kindreds), no correlations were found 
between mutation positions and the occurrence of specific 
clinical features such as dilated cardiomyopathy [24,41]. 
Interestingly, in a larger phenotype and genotype analysis, 
Marshall et al. [7] found a suggestive correlation for 
mutations in exon 8 and normal renal function. 
  Common variations in loci tightly linked to ALMS1 have 
been shown to be associated with kidney disease [75]. In a 
genome-wide association study of cohorts from within the 
CKDGen consortium, an association was found for a SNP 
residing in close proximity to ALMS1, rs13538, and renal 
filtration rate. In 22,982 Caucasian individuals, the 
association was confirmed for renal marker, cystatin C 
(eGFRcys) [76]. Chambers et al. [77] also showed an 
association with SNP rs10206899 (lies in close proximity to 
ALMS1) and serum creatinine levels. In small population-
based association studies in the UK and The Netherlands, no 
associations were found among common variants in ALMS1 
and T2DM [78,79]. However, in an extensive population 
genomic analysis of ALMS1, Scheinfeldt et al. [74] showed 
that variations in ALMS1 may contribute to interindividual 
differences in metabolic phenotypes.  
ANIMAL AND CELLULAR MODELS OF ALSTRÖM 
SYNDROME 
  Several mouse models for Alström syndrome, including 
gene-trapped, ENU-mutagenized and spontaneous mutations, 
have been well characterized [13,16,80]. These models 
recapitulate the features observed in individuals with 
Alström syndrome and, therefore, have the potential to 
provide new insights into the mechanisms of many of the 
fundamental pathologic features of Alström syndrome (Table 
1). In addition, many of the phenotypes observed in the 
animal models, such as retinal degeneration, obesity, and 
fibrosis, can be modified by the genetic background, 
suggesting that the variability seen in the human population 
may also be, at least in part, due to genetic modifiers. Alstrom Syndrome  Current Genomics, 2011, Vol. 12, No. 3    231 
Mouse Models 
Alms1
Gt(XH152)Byg 
 The  Alms1 gene-trapped mouse model, Alms1
GT/GT, 
exhibits most of the classic disease phenotypes found in 
individuals with Alström syndrome [13]. Alms1
GT/GT mice 
were not hyperphagic, nor did they display alterations in 
energy consumption before the increase in body weight and 
the resulting hyperleptinemia (unpublished results). 
Ultrastructural examination of cilia in Alms1
GT/GT mice 
showed normal ciliogenesis in renal tubules, nasal epithelial 
cells, and photoreceptors. In the cochlea, ALMS1 
immunolocalizes to the basal bodies of the kinocilium and 
stereocilia with lesions in the stria vascularis, and 
abnormalities in the hair cell stereociliary bundles indicative 
of planar cell polarity defects [67]. 
Alms1
foz 
 Another  mouse  model,  fat aussie (foz/foz), like the gene 
trap model, exhibits several of the pathologies found in 
Alström  syndrome.  Foz/foz mice fed a normal chow diet 
develop simple steatosis, while those fed a high fat diet 
develop nonalcoholic steatohepatitis [80-82]. Short term 
therapeutic studies with Wy-14, 643, a peroxisome 
proliferation activator receptor alpha (PPAR-) agonist, 
have shown that enhancement of fatty acid oxidation reduced 
steatosis. However, the treatment failed to restore sinusoidal 
blood flow in foz/foz livers [83]. 
Table 1. Murine Models and Human Comparison with Alström Syndrome 
 Human  ALMS1  Mouse Models - ALMS1 homolog (human) 
   Alms1
Gt(XH152)Byg Alms1
foz (fat aussie)  Alms1
L2131X 
References   [13,67]  [80-82] [16] 
Mutation 
Type 
Spontaneous; nonsense and 
frameshift 
Gene trap insertion in intron 13  Spontaneous; 11 bp deletion in 
exon 8 
ENU-induced; nonsense 
mutation in exon 10 
Vision  Cone-rod dystrophy; 
photophobia/nystagmus <1 
year 
Abnormal cone-rod ERG, Slowly 
progressive photoreceptor 
degeneration; accumulation of 
intracellular vesicles; 
mislocalization of rhodopsin  
Not assessed  Impaired rhodopsin transport 
Hearing  Sensorineural loss in >85%  Abnormal ABR; abnormal 
stereocilia; loss of OHC & 
lesions in stria vascularis 
Abnormal ABR >1 year  Not assessed 
Obesity  100% in children, moderates 
to high normal weight in 
adults 
Onset 8-12 weeks  Onset by 3 months. Males and 
females hyperphagic  
Onset 7-10 weeks 
T2DM  95% in children over age  
15 year 
Early hyperinsulinemia; Males 
are overtly hyperglycemic (>16 
weeks); females have elevated 
glucose levels 
Hyperinsulinemia by 60 days; 
pancreatic islet hyperplasia and 
islet cysts; Male and female 
diabetic 
Hyperinsulinemia, but majority 
are normoglycemic 
Lipids  Hypertriglyceridemia; 
hypercholesterolemia  
Hypercholesterolemia; normal 
triglycerides 
Hypercholesterolemia; normal 
triglycerides 
Hypercholesterolemia and 
elevated triglycerides 
Cardiac  Dilated/hypertrophic 
cardiomyopathy 
Unknown Unknown Unknown 
Hypo-
gonadism 
<80% males; amenorrhea in 
females 
Male hypogonadic, atrophic 
seminiferous tubules; lack of 
sperm 
Females fertile prior to obesity.  
Females fertile prior to obesity; 
males are sterile; progressive 
germ cell loss; block of 
development of spermatids; 
flagellation defects 
Males have defective sperm 
formation 
Renal  Glomerulosclerosis  Enlarged kidneys; dilation of 
proximal tubules; proteinurea; 
aged mice may develop renal 
cysts 
Dilated cortical tubules, and older 
animals showed loss of cilia from 
kidney proximal tubules 
Dilated cortical tubules; 
proteinurea; specific loss of cilia 
from the kidney proximal 
tubules in aged mice 
Hepatic  Steatosis, cirrhosis, 
hepatosplenomegaly, 
fibrosis 
Steatosis, hepatosteatitis; fibrosis  Chow diet: steatosis: High fat 
diet: hepatosteatitis, inflammation, 
and fibrosis 
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Alms1
L2131X 
  In the ENU-induced Alms1
L2131X/L2131X mice, collecting 
renal tubules develop normal primary cilia. However, the 
cortical tubules show some loss of cilia as the mouse ages. In 
vitro knockdown of the disease allele inhibited ciliogenesis, 
thereby suggesting some residual function of ALMS1 [16]. 
In Vitro Studies  
Mouse Renal Inner Medullary Collecting Duct (mIMCD) 
Cells 
 In  vitro knockdown of the 5’ end of ALMS1 in mIMCD 
cells using short interfering RNA (siRNA) resulted in 
abnormally stunted renal cilia, which were unable to induce 
calcium flux in response to environmental cues [16]. These 
results support a role for ALMS1 in ciliogenesis and ciliary 
function.  However, loss of ALMS1 did not alter 
transcriptional control of ciliary genes.  
3T3L1 Cells 
  Expression studies of preadipocytes from 3T3L1 cells 
induced with adipogenic factors showed that Alms1 
expression decreases during the differentiation of 
preadipocytes to mature adipocytes. However, treatment of 
preadipocytes with adipogenic factors did not significantly 
modify Alms1 expression, suggesting a role of the gene in 
the early phase of adipogenesis [17]. Moreover, knockdown 
of  Alms1 in 3T3L1 cells showed impairment in adipocyte 
differentiation but does not appear to have an effect on cell-
autonomous insulin action [84]. These results suggest that 
partial impairment of adipogenesis in Alström syndrome 
may contribute to the severity of the associated metabolic 
phenotype.  
Human Primary Fibroblasts 
  To explore the hypothesis that a defect in adipogenesis 
and/or insulin action in mature adipocytes leads to relative 
failure of metabolic homeostasis, dermal fibroblasts derived 
from Alström syndrome individuals were examined in vitro. 
Insulin receptor mRNA is increased, despite normal early 
signaling events in response to insulin and normal insulin-
dependent glucose uptake [85].  
CONCLUSION 
  Alström syndrome is a complex pleiotropic disorder 
caused by mutations in ALMS1. Systemic characteristics of 
this disorder include truncal obesity, hyperinsulinemia, and 
T2DM, acanthosis nigricans, short adult stature, and vision 
and hearing loss, dilated or restrictive cardiomyopathy 
(infancy or adolescence/adulthood) with CHF, 
hypothyroidism and hypogonadism. Death usually occurs 
due to progressive cardiac, hepatic and renal failure, often 
associated with pulmonary disease. The cellular and 
molecular mechanisms underlying the disorder remain to be 
understood although widespread severe fibrosis may 
significantly contribute to the disease pathology. Studies in 
murine and cellular models suggest that defects in 
ciliogenesis and/or structure, function, or maintenance of 
cilia underlie the pathogenesis of Alström syndrome [13-
16,68].  
  The consequences of centrosome, ciliary, and/or IFT 
system deficits in the hypothalamic pathways for metabolic 
abnormalities leading to obesity are not well understood. It 
has been hypothesized that loss of functioning ALMS1 could 
impact the cilia on hypothalamic neurons and lead to 
alteration in behavior and energy homeostasis, through 
abnormal perception of appetite and satiety cues, such as 
leptin, resulting in overeating and obesity [86]. In other 
organ systems such as the cochlea and the proximal renal 
tubules, planar cell polarity defects, which are often 
observed in ciliopathies, may play a role. In yet other organs, 
such as the heart, the role of ALMS1 in the pathology is 
entirely unclear. However, the knowledge that ALMS1 is a 
ciliary protein and plays a role in normal centrosome/basal 
body function and their associated intracellular trafficking 
events allows new hypotheses to be formulated and to make 
further progress in understanding and treating Alström 
syndrome.  
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ABBREVIATIONS 
ABR  =  Auditory brainstem response 
ARDS  =  Acute respiratory distress syndrome 
BBS =  Bardet-Biedl  Syndrome 
BMI  =  Body mass index (kg/m
2) 
CHF  =  Congestive heart failure 
CNAP1  =  Centrosome cohesion protein 
COPD  =  Chronic obstructive pulmonary disease 
CPAP  =  Continuous positive air pressure 
DCM =  Dilated  cardiomyopathy 
DEXA  =  Dual energy x-ray absorptiometry 
ERG =  Electroretinography 
ESRD  =  End stage renal disease 
IGF  =  Insulin-like growth factor 
IFT =  Intraflagellar  transport 
LCA  =  Leber’s congenital amaurosis 
mIMCD =  Mouse renal inner medullary collecting duct 
cells 
OCT  =  Optical coherence tomography 
OHC =  Outer  hair  cells 
RPE  =  Retinal pigment epithelium 
SNP  =  Single nucleotide polymorphism 
T2DM  =  Type 2 diabetes mellitus 
TF =  Transcription  factor 
TSS  =  Transcription start site 
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